Pfizer, Occidental Petroleum, Bank of America and more

Find out which companies are making the headlines before the bell:

Evergrande Group in China – Chinese real estate giant Evergrande fell more than 10% on the Hong Kong Stock Exchange, scaring Asian markets. The company has struggled to pay its suppliers and has warned investors twice in as many weeks that it could default on its debts. Last week, Evergrande said its real estate sales would likely continue to drop significantly in September after falling for months.

Pfizer – The pharmaceutical giant said on Monday that trials have shown its Covid vaccine to be safe and effective when used in children aged 5 to 11. Pfizer and its partner BioNTech said they would submit the results for approval “as soon as possible”. Pfizer shares fell about 1% in pre-market trading.

Laredo Petroleum, Occidental Petroleum – Oil and energy stocks fell in pre-market trading Monday. The SPDR S&P Oil & Gas Exploration ETF was down more than 3% at the start of the session, in line with its third consecutive negative session. Laredo Petroleum is down over 8%, Callon Petroleum is down around 6% and Occidental Petroleum is down almost 5%. The losses came when crude oil fell amid fears of a global economic slowdown linked to the Chinese real estate market.

Colgate-Palmolive – The consumer staples share was revalued to be bought by Deutsche Bank on Sunday. The investment firm said Colgate’s struggles with inflation and some international markets were already built into its stock.

JPMorgan, Bank of America – Bank stocks slipped in unison amid falling bond yields amid fears of a slowdown. Investors have flocked to Treasuries for security reasons as the stock market is on the verge of its biggest sell-off in months. Large bank stocks were hit as lower rates could hurt earnings. Bank of America and JPMorgan Chase each lost more than 2% in pre-market trade. Citizens Financial Group fell 3%, while Citigroup fell 2.5%.

AstraZeneca – The UK-based pharmaceutical company announced Monday that its breast cancer drug Enhertu has shown positive results in a phase three trial. The company’s shares rose more than 1% in pre-market trading.

ARK Innovation ETF – Cathie Wood’s ARK Innovation ETF is down 2.75% in pre-release, on the verge of a 3-day streak of straight wins. Compugen, DraftKings, Coinbase and Square are therefore the biggest losers in the ETF this morning.

– with reporting from CNBC’s Jesse Pound and Yun Li.